Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Oral consumption of α-linolenic acid increases serum BDNF levels in healthy adult humans

  • Mahmoudreza Hadjighassem1, 5Email author,
  • Behnam Kamalidehghan2,
  • Nima Shekarriz3,
  • Argavan Baseerat3,
  • Nima Molavi3,
  • Masoud Mehrpour4,
  • Mohammad Taghi Joghataei1, 6,
  • Mahdi Tondar7,
  • Fatemeh Ahmadipour2 and
  • Goh Yong Meng8
Nutrition Journal201514:20

https://doi.org/10.1186/s12937-015-0012-5

Received: 6 November 2014

Accepted: 16 February 2015

Published: 26 February 2015

Abstract

Background aims

Dietary omega-6 and omega-3 fatty acids have remarkable impacts on the levels of DHA in the brain and retina. Low levels of DHA in plasma and blood hamper visual and neural development in children and cause dementia and cognitive decline in adults. The level of brain-derived neurotrophic factors (BDNF) changes with dietary omega-3 fatty acid intake. BDNF is known for its effects on promoting neurogenesis and neuronal survival.

Methods

In this study, we examined the effect of the oral consumption of α-Linolenic acid (ALA) on blood levels of BDNF and Malondialdehyde (MDA) in healthy adult humans. 30 healthy volunteers, 15 men and 15 women, were selected randomly. Each individual served as his or her own control. Before consuming the Flaxseed oil capsules, 5cc blood from each individual was sampled in order to measure the plasma levels of BDNF and MDA as baseline controls. During the experiment, each individual was given 3 oral capsules of flaxseed oil, containing 500mg of alpha linolenic acid, daily for one week. Then, plasma levels of BDNF and MDA were tested.

Results

The plasma levels of BDNF and MDA significantly (P < 0.05) increased in individuals who received the oral capsules of ALA. Plasma levels of BDNF increased more in the women in comparison with the men.

Conclusion

ALA treatment could be a feasible approach to reduce size of infarcts in stroke patients. Thus, ALA could be used in adjunction with routine stroke therapies to minimize brain lesions caused by stroke.

Keywords

α-Linolenic acid Oral consumption BDNF level Neuroprotective effects Stroke

Introduction

The long chain omega-3 fatty acid with 6 double bonds and 22 carbons, docosahexaenoic acid (DHA), is the most abundant omega-3 fatty acid in the mammalian central nervous system. DHA is concentrated in the visual units of retina and membrane lipids of the brain grey matter. Levels of DHA increase during mammalian development and reduce by aging [1-5].

Many researchers have shown that dietary ω-6 and omega ω-3 fatty acids have remarkable impact on the levels of DHA in brain and retina [6,7]. Furthermore, according to many epidemiological studies, low levels of DHA in plasma and blood hamper visual and neural development in children and cause dementia and cognitive decline in adults [8-22].

A growing body of evidence indicates that omega-3 fatty acids have neuroprotective impact on the nervous system. These fatty acids influence the levels of neurotrophins, molecules that increase neuronal growth and survival. Among neurotrophins, the level of brain-derived neurotrophic factor (BDNF) changes with dietary omega-3 fatty acids intake [23,24]. BDNF is known for its effects on promoting neurogenesis and neuronal survival [25,26].

The α-Linolenic acid (ALA; 18:3n - 3) is a polyunsaturated omega-3 fatty acid that has several neuroprotective effects [27-32]. In this study, we measured the plasma levels of BDNF and MDA in two groups of healthy participants, those who received ALA and those who did not.

Material and methods

This study was evaluated and approved by the Ethical Committee of the Tehran University of Medical Sciences. Thirty healthy volunteers, fifteen men and fifteen women, were selected randomly. They read and signed a consent form prior to enrolment in this study. These individuals had Body Mass Indexes (BMI) of less than thirty, similar low-fat diets, and no underlying diseases such as diabetes or high blood pressure. Because effective doses of ALA for increasing BDNF levels are unknown, each individual served as his or her own control.

Before consuming the Flaxseed oil [(Swiss, Canada) (Table 1)], 5cc blood from each individual was sampled in order to measure the plasma levels of BDNF and MDA as baseline controls. During the experiment, each individual was given 3 oral capsules of flaxseed oil, containing 500mg of ALA, daily for one week. Then, Plasma levels of BDNF and MDA were assessed using BDNF Emax® ImmunoAssay (Promega) and colorimetric Assay (Oxford Biomedical Research) kits according to the manufacturer’s protocols, respectively.
Table 1

Flax seed oil capsules

Flax seed oil

ALA

Company

1000 mg

530 mg

Swissherbal

Each 1000 mg flax seed oil capsule contained 530 mg ALA.

Statistical analysis

GraphPad prism5 was applied to compare the levels of BDNF and MDA, after taking the capsules for one week, to their baselines. Numerical data are presented below as means ± SEM. Statistical testing used Paired t-test analysis. Each test was performed at least two times and P < 0.05 was considered significant.

Results

This study revealed that plasma BDNF levels significantly (P < 0.05) increased in individuals who received the oral capsules of ALA (Figure 1). In order to determine whether or not this phenomenon was associated with peroxidation of fatty acids, plasma levels of MDA in the ALA group were measured, and they notably (p < 0.05) increased. (Figure 2)
Figure 1

Plasma level of BDNF. Plasma Levels of BDNF were detected by ELISA. Data were analyzed by GraphPad prism5. Bars refer to the Mean and SEM with P < 0.05.

Figure 2

Plasma level of MDA. Plasma Levels of MDA were measured before (cont) and after intake of Flax seed oil. Bars represent the SEM with P < 0.05.

.
In addition, plasma levels of BDNF increased more in the women in comparison with the men. Although we observed a significant positive trend in increasing the BDNF levels in the men (P = 0.01) (Table 2, Figure 3).
Table 2

Data analysis of serum BDNF levels in males and females

Sex

 

Pretreatment

Post-treatment

P value

 

Mean

Female

0.7987

1.036

0.005

Std.Deviation

 

0.1740

0.2035

 

Mean

Male

0.8872

1.096

0.01

Std.Deviation

 

0.1270

0.1986

 
Figure 3

Sex dependency of BDNF change. BDNF levels were compared between the males and females before and after receiving the capsules.

Discussion

The neuroprotective roles of ALA have been reported in several stroke studies [27,31-36]. Recently, several molecular and clinical studies emphasized on the therapeutic potential of Omega-3 polyunsaturated fatty acids for treating a number of neurological and psychiatric diseases. Nevertheless, the mechanisms underlying these effects are still poorly understood.

In 2009, Blondeau et al. showed that subchronic ALA injections in mice induced neurogenesis in the hippocampus, increased in vivo and in vitro BDNF expression, promoted Neural Stem cell (NSCs) proliferation and synaptogenesis, enhanced synaptic vesicle fusion and protein levels, and induced antidepressant-like behavior. Furthermore, they observed that pre- and post-treatments with repeated ALA injections decreased the infarc volumes and mortality caused by middle cerebral artery occlusion (MCAO) [37]. Nguemeni et al. in 2010 reported that dietary supplements of ALA in an enriched rapeseed oil diet could significantly reduce the MCAO-induced mortality rate and infarct volumes in mice [38]. In light of these studies on ALA, we examined the effect of dietary consumption of ALA on the blood levels of BDNF and MDA. To the best of our knowledge, this is the first study on healthy adult humans that measured both BDNF and MDA levels, used oral consumption of ALA, and determined sex differences in response to ALA intake. The results demonstrated that the levels of BDNF and MDA both increased in individuals who took ALA.

Neurotrophins are small proteins that are crucial for neuronal differentiation, growth, survival, and plasticity [39]. Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) are members of the mammalian neurotrophin family. The impact of these molecules on the nervous system is mediated by the tropomyosin receptor kinase (Trk) receptors and membrane-bound receptor tyrosine kinases that activate a number of cell signaling pathways which are linked to growth, differentiation, and survival [40]. The importance of neurotrophin signaling in brain development is well elucidated with findings that showed that knockout mice for any of the neurotrophins or their receptors were fatal or exhibited severe neural defects [41]. Neurotrophin signallings have important roles in the survival and integration of new neurons. For instance, BDNF triggers the TrkB receptor tyrosine kinases. BDNF also increases the number and survival of NSCs in the subventricular zone (SVZ) and olfactory bulbs [42,43]. Likewise, knocking down the TrkB receptors or disrupting the BDNF signaling pathway in dentate gyrus progenitors can lead to the formation of shorter dendrites, reduced spine, and eventually death [44].

BDNF signaling promotes the survival of newly-generated neurons. In addition, defects in this pathway are associated with decreased neuronal survival and neurogenesis as well as the incidence and progression of several neurological disorders, such as schizophrenia, bipolar disorder, Alzheimer’s disease, and age-related cognitive decline [43,45,46]. Furthermore, BDNF indirectly increases the transcription of Bcl-w gene, an anti-apoptotic member of the Bcl-2 family [47]. Thus, BDNF decreases neuronal apoptosis. In addition, BDNF increases adhesion, migration, and survival of neurons. This neurotrophic molecule also enhances neurogenesis, synaptic plasticity, and neuronal differentiation through the BDNF/TrkB-TK+ signaling pathway, an important pathway for neuronal viability and function [48-57].

ALA treatment can be beneficial for the treatment of many neurological diseases, particularly stroke, which is the third leading cause of death worldwide [58,59]. Our findings were in accordance with the previous studies, confirming that ALA increases the expression of BDNF. Considering the neuroprotective and neurotrophic characteristics of BDNF, ALA treatment could be a feasible approach to reduce infarct size in stroke patients. Thus, ALA could be used in adjunction with routine stroke treatments to minimize lesions caused by stroke. Further research could attempt to replicate the present findings with a larger sample size. Furthermore, studying the molecular mechanisms underlying the positive effects of ALA on the nervous system might also be helpful. Future research can investigate the effects of ALA intake on stroke patients.

Abbreviations

ALA: 

α-Linolenic Acid

BDNF: 

Braine-derived Neurotrophic Factor

DHA: 

Docosahexaenoic acid

MDA: 

Malondialdehyde

Declarations

Acknowledgements

This research was funded by a grant from the Cellular and Molecular Research Center at the Iran University of Medical Sciences (No. 12507).

Authors’ Affiliations

(1)
Cellular and Molecular Research Center, Iran University of Medical Sciences
(2)
Department of Pharmacy, Faculty of Medicine, University of Malaya (UM)
(3)
Faculty of Medicine, Iran University of Medical Sciences
(4)
Department of Neurology, Faculty of Medicine, Iran University of Medical Sciences
(5)
Brain and Spinal Cord Research Center, School of Advanced Medical Technologies, Tehran University of Medical Sciences
(6)
Department of Anatomy, Faculty of Medicine, Iran University of Medical Sciences
(7)
Department of Biochemistry and Molecular & Cellular Biology, Georgetown University
(8)
Department of Animal Science, Faculty of Veterinary Medicine, Universiti Putra Malaysia

References

  1. Giusto NM, Salvador GA, Castagnet PI, Pasquare SJ, Ilincheta de Boschero MG. Age-associated changes in central nervous system glycerolipid composition and metabolism. Neurochem Res. 2002;27:1513–23.View ArticlePubMedGoogle Scholar
  2. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992;120:S129–38.View ArticlePubMedGoogle Scholar
  3. Rotstein NP, Ilincheta de Boschero MG, Giusto NM, Aveldano MI. Effects of aging on the composition and metabolism of docosahexaenoate-containing lipids of retina. Lipids. 1987;22:253–60.View ArticlePubMedGoogle Scholar
  4. Soderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. J Neurochem. 1990;54:415–23.View ArticlePubMedGoogle Scholar
  5. Svennerholm L. Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res. 1968;9:570–9.PubMedGoogle Scholar
  6. Innis SM. Essential fatty acids in growth and development. Prog Lipid Res. 1991;30:39–103.View ArticlePubMedGoogle Scholar
  7. Innis SM. Essential fatty acid metabolism during early development. In: Biology of Metabolism in Growing Animals. B.V. Amsterdam: Elsevier Science; 2005.Google Scholar
  8. Bouwstra H, Dijck-Brouwer DA, Wildeman JA, Tjoonk HM, van der Heide JC, Boersma ER, et al. Long-chain polyunsaturated fatty acids have a positive effect on the quality of general movements of healthy term infants. Am J Clin Nutr. 2003;78:313–8.PubMedGoogle Scholar
  9. Dullemeijer C, Durga J, Brouwer IA, van de Rest O, Kok FJ, Brummer RJ, et al. n 3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr. 2007;86:1479–85.PubMedGoogle Scholar
  10. Dunstan JA, Simmer K, Dixon G, Prescott SL. Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2008;93:F45–50.View ArticlePubMedGoogle Scholar
  11. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age. Pediatrics. 2003;111:e39–44.View ArticlePubMedGoogle Scholar
  12. Hibbeln JR, Davis JM, Steer C, Emmett P, Rogers I, Williams C, et al. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. Lancet. 2007;369:578–85.View ArticlePubMedGoogle Scholar
  13. Innis SM, Friesen RW. Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants. Am J Clin Nutr. 2008;87:548–57.PubMedGoogle Scholar
  14. Innis SM, Gilley J, Werker J. Are human milk long-chain polyunsaturated fatty acids related to visual and neural development in breast-fed term infants? J Pediatr. 2001;139:532–8.View ArticlePubMedGoogle Scholar
  15. Kalmijn S, van Boxtel MP, Ocke M, Verschuren WM, Kromhout D, Launer LJ. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004;62:275–80.View ArticlePubMedGoogle Scholar
  16. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003;60:940–6.View ArticlePubMedGoogle Scholar
  17. Nurk E, Drevon CA, Refsum H, Solvoll K, Vollset SE, Nygard O, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr. 2007;86:1470–8.PubMedGoogle Scholar
  18. Oken E, Wright RO, Kleinman KP, Bellinger D, Amarasiriwardena CJ, Hu H, et al. Maternal fish consumption, hair mercury, and infant cognition in a U.S. Cohort. Environ Health Perspect. 2005;113:1376–80.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Schaeffer L, Gohlke H, Muller M, Heid IM, Palmer LJ, Kompauer I, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet. 2006;15:1745–56.View ArticlePubMedGoogle Scholar
  20. Uauy R, Dangour AD. Nutrition in brain development and aging: role of essential fatty acids. Nutr Rev. 2006;64:S24–33. discussion S72-91.View ArticlePubMedGoogle Scholar
  21. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007;85:1142–7.PubMedGoogle Scholar
  22. Williams C, Birch EE, Emmett PM, Northstone K. Avon Longitudinal Study of P, Childhood Study T. Stereoacuity at age 3.5 y in children born full-term is associated with prenatal and postnatal dietary factors: a report from a population-based cohort study. Am J Clin Nutr. 2001;73:316–22.PubMedGoogle Scholar
  23. Beltz BS, Tlusty MF, Benton JL, Sandeman DC. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett. 2007;415:154–8.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma. 2004;21:1457–67.View ArticlePubMedGoogle Scholar
  25. Loeliger MM, Briscoe T, Rees SM. BDNF increases survival of retinal dopaminergic neurons after prenatal compromise. Invest Ophthalmol Vis Sci. 2008;49:1282–9.View ArticlePubMedGoogle Scholar
  26. Mattson MP, Maudsley S, Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev. 2004;3:445–64.View ArticlePubMedGoogle Scholar
  27. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience. 2002;109:231–41.View ArticlePubMedGoogle Scholar
  28. Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, et al. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004;23:2684–95.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Huang WL, King VR, Curran OE, Dyall SC, Ward RE, Lal N, et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain. 2007;130:3004–19.View ArticlePubMedGoogle Scholar
  30. King VR, Huang WL, Dyall SC, Curran OE, Priestley JV, Michael-Titus AT. Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci. 2006;26:4672–80.View ArticlePubMedGoogle Scholar
  31. Lang-Lazdunski L, Blondeau N, Jarretou G, Lazdunski M, Heurteaux C. Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J Vasc Surg. 2003;38:564–75.View ArticlePubMedGoogle Scholar
  32. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J. 2000;19:1784–93.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Blondeau N, Petrault O, Manta S, Giordanengo V, Gounon P, Bordet R, et al. Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res. 2007;101:176–84.View ArticlePubMedGoogle Scholar
  34. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci. 2001;21:4668–77.PubMedGoogle Scholar
  35. Heurteaux C, Laigle C, Blondeau N, Jarretou G, Lazdunski M. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience. 2006;137:241–51.View ArticlePubMedGoogle Scholar
  36. Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na + currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na + channel. Proc Natl Acad Sci U S A. 1998;95:2680–5.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Blondeau N, Nguemeni C, Debruyne DN, Piens M, Wu X, Pan H, et al. Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuropsychopharmacology. 2009;34:2548–59.View ArticlePubMedGoogle Scholar
  38. Nguemeni C, Delplanque B, Rovere C, Simon-Rousseau N, Gandin C, Agnani G, et al. Dietary supplementation of alpha-linolenic acid in an enriched rapeseed oil diet protects from stroke. Pharmacol Res. 2010;61:226–33.View ArticlePubMedGoogle Scholar
  39. Schindowski K, Belarbi K, Buee L. Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav. 2008;7 Suppl 1:43–56.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–80.View ArticlePubMedGoogle Scholar
  41. Bartkowska K, Turlejski K, Djavadian RL. Neurotrophins and their receptors in early development of the mammalian nervous system. Acta Neurobiol Exp. 2010;70:454–67.Google Scholar
  42. Bath KG, Mandairon N, Jing D, Rajagopal R, Kapoor R, Chen ZY, et al. Variant brain-derived neurotrophic factor (Val66Met) alters adult olfactory bulb neurogenesis and spontaneous olfactory discrimination. J Neurosci. 2008;28:2383–93.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Kirschenbaum B, Goldman SA. Brain-derived neurotrophic factor promotes the survival of neurons arising from the adult rat forebrain subependymal zone. Proc Natl Acad Sci U S A. 1995;92:210–4.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Bergami M, Rimondini R, Santi S, Blum R, Gotz M, Canossa M. Deletion of TrkB in adult progenitors alters newborn neuron integration into hippocampal circuits and increases anxiety-like behavior. Proc Natl Acad Sci U S A. 2008;105:15570–5.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008;1144:97–112.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10:209–19.View ArticlePubMedGoogle Scholar
  47. Pazyra-Murphy MF, Hans A, Courchesne SL, Karch C, Cosker KE, Heerssen HM, et al. A retrograde neuronal survival response: target-derived neurotrophins regulate MEF2D and bcl-w. J Neurosci. 2009;29:6700–9.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Allen SJ, Wilcock GK, Dawbarn D. Profound and selective loss of catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem Biophys Res Commun. 1999;264:648–51.View ArticlePubMedGoogle Scholar
  49. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res Mol Brain Res. 1997;49:71–81.View ArticlePubMedGoogle Scholar
  50. Fahnestock M, Garzon D, Holsinger RM, Michalski B. Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule? J Neural Transm Suppl. 2002;62:241–52.View ArticlePubMedGoogle Scholar
  51. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol. 1999;58:729–39.View ArticlePubMedGoogle Scholar
  52. Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer’s disease parietal cortex. J Neurochem. 2002;82:1058–64.View ArticlePubMedGoogle Scholar
  53. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol. 2000;57:846–51.View ArticlePubMedGoogle Scholar
  54. Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res Mol Brain Res. 2000;76:347–54.View ArticlePubMedGoogle Scholar
  55. Michalski B, Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res. 2003;111:148–54.View ArticlePubMedGoogle Scholar
  56. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93:1412–21.View ArticlePubMedGoogle Scholar
  57. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron. 1991;7:695–702.View ArticlePubMedGoogle Scholar
  58. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:948–54.View ArticlePubMedGoogle Scholar
  59. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–146.View ArticlePubMedGoogle Scholar

Copyright

© Hadjighassem et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

Advertisement